{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:49:23Z","timestamp":1785307763599,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-00556"],"award-info":[{"award-number":["2022-00556"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107325","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:09:18Z","timestamp":1760400558000},"page":"107325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Linker modifications in radiolabeled RM26-based antagonists to gastrin-releasing peptide receptor (GRPR) improved tracers\u2019 pharmacokinetics"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-5719","authenticated-orcid":false,"given":"Ekaterina","family":"Bezverkhniaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Abouzayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kanellopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Rosenstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107325_bib0001","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2967\/jnumed.111.094375","article-title":"Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors","volume":"52","author":"Abiraj","year":"2011","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejps.2025.107325_bib0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/pharmaceutics13020182","article-title":"Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS\/SES-PEG2-RM26 for imaging of prostate cancer","volume":"13","author":"Abouzayed","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107325_bib0003","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/biom13071134","article-title":"Preclinical characterization of a stabilized gastrin-releasing peptide receptor antagonist for targeted cancer theranostics","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejps.2025.107325_bib0004","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/diagnostics13091611","article-title":"The GRPR antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards phase I clinical trial: kit preparation, characterization and toxicity","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.ejps.2025.107325_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejps.2025.107325_bib0006","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2967\/jnumed.119.234971","article-title":"Imaging the distribution of gastrin-releasing peptide receptors in cancer","volume":"61","author":"Baratto","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.ejps.2025.107325_bib0007","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cmdc.201000191","article-title":"Synthesis and evaluation of Bombesin analogues conjugated to two different triazolyl-derived chelators for 99mTc labeling","volume":"5","author":"Brans","year":"2010","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.ejps.2025.107325_bib0008","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/cancers15061631","article-title":"Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors","volume":"15","author":"Chernov","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107325_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1250799","article-title":"GRPR-targeting radiotheranostics for breast cancer management","volume":"10","author":"D\u2019Onofrio","year":"2023","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.ejps.2025.107325_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0969-8051(98)00118-8","article-title":"99m-technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution","volume":"26","author":"Decristoforo","year":"1999","journal-title":"Nucl. Med. Biol."},{"issue":"12","key":"10.1016\/j.ejps.2025.107325_bib0011","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2967\/jnumed.121.263611","article-title":"Using 68Ga-PSMA-11 PET\/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: application of EAU\/EANM recommendations in clinical practice","volume":"63","author":"Denis","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.ejps.2025.107325_bib0012","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/ijms25084246","article-title":"Preclinical evaluation of HER2-targeting DARPin G3: impact of albumin binding domain (ABD) fusion","volume":"25","author":"Deyev","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejps.2025.107325_bib0013","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/cancers11081168","article-title":"Incorporation of a hydrophilic spacer reduces hepatic uptake of HER2-targeting affibody-DM1 drug conjugates","volume":"11","author":"Ding","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107325_bib0014","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00259-007-0474-6","article-title":"99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific affibody molecule","volume":"34","author":"Engfeldt","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.ejps.2025.107325_bib0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ejps.2025.107325_bib0016","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/diagnostics11091555","article-title":"Breast cancer heterogeneity","volume":"11","author":"Fumagalli","year":"2021","journal-title":"Diagnostics"},{"issue":"12","key":"10.1016\/j.ejps.2025.107325_bib0017","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1021\/bc800262m","article-title":"Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core","volume":"19","author":"Garc\u00eda Garayoa","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2025.107325_bib0018","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3390\/pharmaceutics14081612","article-title":"Experimental HER2-targeted therapy using ADAPT6-ABD-mcDM1 in mice bearing SKOV3 ovarian cancer xenografts: efficacy and selection of companion imaging counterpart","volume":"14","author":"Garousi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2025.107325_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00006676-199601000-00004","article-title":"Expression and characterization of gastrin-releasing peptide receptor in normal and cancerous pancreas","volume":"12","author":"Hajri","year":"1996","journal-title":"Pancreas"},{"issue":"8","key":"10.1016\/j.ejps.2025.107325_bib0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","volume":"14","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.ejps.2025.107325_bib0021","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0969-8051(94)90175-9","article-title":"Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies?","volume":"21","author":"Hnatowich","year":"1994","journal-title":"Nucl. Med. Biol."},{"issue":"21\u201322","key":"10.1016\/j.ejps.2025.107325_bib0022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.drudis.2012.07.002","article-title":"Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design","volume":"17","author":"Hosseinimehr","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.ejps.2025.107325_bib0023","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.semdp.2022.06.015","article-title":"Update on prognostic and predictive biomarkers of breast cancer","volume":"39","author":"Hou","year":"2022","journal-title":"Semin. Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.ejps.2025.107325_bib0024","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.nucmedbio.2014.03.014","article-title":"PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists","volume":"41","author":"Jamous","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2025.107325_bib0025","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cpet.2017.02.007","article-title":"Theranostic prospects of gastrin-releasing peptide receptor-radioantagonists in oncology","volume":"12","author":"Maina","year":"2017","journal-title":"PET Clin."},{"key":"10.1016\/j.ejps.2025.107325_bib0026","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"issue":"1\u20134","key":"10.1016\/j.ejps.2025.107325_bib0027","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/rpd\/ncv061","article-title":"Patient dosimetry in nuclear medicine","volume":"165","author":"Mattsson","year":"2015","journal-title":"Radiat. Prot. Dosimetry"},{"key":"10.1016\/j.ejps.2025.107325_bib0028","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-005-1793-0","article-title":"Localisation and mechanism of renal retention of radiolabelled somatostatin analogues","volume":"32","author":"Melis","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"10.1016\/j.ejps.2025.107325_bib0029","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.01.001","article-title":"Diagnostic value of gastrin-releasing peptide receptor-targeted PET imaging in oncology: a systematic review","author":"Mohseninia","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ejps.2025.107325_bib0030","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1432 primary tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2025.107325_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.926258","article-title":"New strategies for a sustainable 99mTc supply to meet increasing medical demands: promising solutions for current problems","volume":"10","author":"Nawar","year":"2022","journal-title":"Front. Chem."},{"issue":"7","key":"10.1016\/j.ejps.2025.107325_bib0032","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1021\/acs.jmedchem.8b00177","article-title":"New gastrin releasing peptide receptor-directed [99mTc]demobesin 1 mimics: synthesis and comparative evaluation","volume":"61","author":"Nock","year":"2018","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejps.2025.107325_bib0033","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.3390\/cancers13205093","article-title":"[99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes","volume":"13","author":"Nock","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2025.107325_bib0034","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/pharmaceutics16040513","article-title":"GRPR-antagonists carrying DOTAGA-chelator via positively charged linkers: perspectives for Prostate Cancer theranostics","volume":"16","author":"Obeid","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejps.2025.107325_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejps.2025.107325_bib0036","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107325_bib0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejps.2025.107325_bib0038","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/bc400343r","article-title":"Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with 18F-4-fluorobenzaldehyde","volume":"25","author":"Rosik","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2025.107325_bib0039","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/cancers15082345","article-title":"Theranostics of primary prostate cancer: beyond PSMA and GRP-R","volume":"15","author":"Schollhammer","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejps.2025.107325_bib0040","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study","volume":"61","author":"Sonni","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejps.2025.107325_bib0041","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.3390\/molecules190710455","article-title":"The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of Bombesin","volume":"19","author":"Varasteh","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2025.107325_bib0042","article-title":"[99mTc]Tc-HYNIC-RM2: a potential SPECT probe targeting GRPR expression in prostate cancers","volume":"118","author":"Vats","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejps.2025.107325_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199432","article-title":"GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches","volume":"13","author":"Verhoeven","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107325_bib0044","article-title":"Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.ejps.2025.107325_bib0045","first-page":"297","article-title":"68Ga-PSMA PET\/CT for the evaluation of metastasis in patients with prostate cancer: a systematic review and meta-analysis","volume":"25","author":"Zhou","year":"2022","journal-title":"Hell J. Nucl. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:09:45Z","timestamp":1763662185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"alternative-id":["S0928098725003239"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107325","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linker modifications in radiolabeled RM26-based antagonists to gastrin-releasing peptide receptor (GRPR) improved tracers\u2019 pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107325"}}